(Q38872460)

7 September 2017

0 references

1 reference

title

Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis (English)

1 reference

chronic lymphocytic leukemia

7 September 2017

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Liang Liang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Yuan-Chao Zhu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Xin Hu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Li-Ping Yang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Hui Liu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

21 June 2016

1 reference

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1473-1482

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

The clinical and epidemiological burden of chronic lymphocytic leukaemia

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Lenalidomide alone and in combination for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

A review of the history, properties, and use of the immunomodulatory compound lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Lenalidomide in the treatment of chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Comment to "Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation" Haematologica. 2012;97(12):1845-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

Targeted therapies in CLL: mechanisms of resistance and strategies for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2719-6

10.1007/S00277-016-2719-6

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27329288%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference